Rosiglitazone And Plaque Study for Type 2 Diabetes Mellitus
Status:
Completed
Trial end date:
2005-05-01
Target enrollment:
Participant gender:
Summary
This is a phase IIIb, randomised, double blind, placebo controlled, study in patients with
type 2 diabetes mellitus and coexisting vascular disease or hypertension. The total duration
of the study will be approximately 60 weeks. The aim of this study is to examine the
potential beneficial effects of rosiglitazone on carotid atheroma in patients with type 2
diabetes mellitus and coexisting vascular disease or hypertension. It is hypothesised that
treatment with rosiglitazone will lead to an decrease in plaque size. In addition, it is
hoped that rosiglitazone will have a positive effect on plaque composition and stability.